CN101951910B - 优化用伊马替尼治疗酪氨酸激酶受体kit介导的增殖性疾病的制药用途 - Google Patents

优化用伊马替尼治疗酪氨酸激酶受体kit介导的增殖性疾病的制药用途 Download PDF

Info

Publication number
CN101951910B
CN101951910B CN2009801027282A CN200980102728A CN101951910B CN 101951910 B CN101951910 B CN 101951910B CN 2009801027282 A CN2009801027282 A CN 2009801027282A CN 200980102728 A CN200980102728 A CN 200980102728A CN 101951910 B CN101951910 B CN 101951910B
Authority
CN
China
Prior art keywords
imatinib
treatment
kit
tyrosine kinase
cmin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN2009801027282A
Other languages
English (en)
Chinese (zh)
Other versions
CN101951910A (zh
Inventor
Y·王
E·韦尔勒
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40435094&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN101951910(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis AG filed Critical Novartis AG
Publication of CN101951910A publication Critical patent/CN101951910A/zh
Application granted granted Critical
Publication of CN101951910B publication Critical patent/CN101951910B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5753—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the stomach or small intestine

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CN2009801027282A 2008-01-23 2009-01-21 优化用伊马替尼治疗酪氨酸激酶受体kit介导的增殖性疾病的制药用途 Expired - Fee Related CN101951910B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US2294508P 2008-01-23 2008-01-23
US61/022,945 2008-01-23
PCT/US2009/031510 WO2009094360A1 (en) 2008-01-23 2009-01-21 Method of optimizing the treatment of proliferative diseases mediated by the tyrosine kinase receptor kit with imatinib

Publications (2)

Publication Number Publication Date
CN101951910A CN101951910A (zh) 2011-01-19
CN101951910B true CN101951910B (zh) 2013-07-17

Family

ID=40435094

Family Applications (1)

Application Number Title Priority Date Filing Date
CN2009801027282A Expired - Fee Related CN101951910B (zh) 2008-01-23 2009-01-21 优化用伊马替尼治疗酪氨酸激酶受体kit介导的增殖性疾病的制药用途

Country Status (14)

Country Link
US (3) US20100298338A1 (https=)
EP (1) EP2237783B1 (https=)
JP (2) JP5936821B2 (https=)
KR (1) KR101579993B1 (https=)
CN (1) CN101951910B (https=)
AU (1) AU2009206566A1 (https=)
BR (1) BRPI0906504A2 (https=)
CA (1) CA2712087A1 (https=)
ES (1) ES2526537T3 (https=)
MX (1) MX2010008103A (https=)
PL (1) PL2237783T3 (https=)
PT (1) PT2237783E (https=)
RU (1) RU2537223C2 (https=)
WO (1) WO2009094360A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2753391C1 (ru) * 2020-09-29 2021-08-13 Государственное бюджетное учреждение здравоохранения Московской области "Московский областной научно-исследовательский клинический институт им. М.Ф. Владимирского" (ГБУЗ МО МОНИКИ им. М.Ф. Владимирского) Способ оптимизации лечения стромальных опухолей желудочно-кишечного тракта

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7125875B2 (en) * 1999-04-15 2006-10-24 Bristol-Myers Squibb Company Cyclic protein tyrosine kinase inhibitors
GB0127922D0 (en) * 2001-11-21 2002-01-16 Novartis Ag Organic compounds
RU2362562C2 (ru) * 2003-11-18 2009-07-27 Новартис Аг Ингибиторы мутантной формы киназы kit
US7329495B2 (en) * 2004-06-09 2008-02-12 Board Of Regents, The University Of Texas System Mutations in KIT confer imatinib resistance in gastrointestinal stromal tumors
MY148074A (en) * 2005-05-10 2013-02-28 Novartis Ag Pharmaceutical compositions comprising imatinib and a release retardant
WO2008036792A2 (en) * 2006-09-22 2008-03-27 Novartis Ag Method of optimizing the treatment of philadelphia-positive leukemia with abl tyrosine kinase inhibitors
NZ577320A (en) 2006-11-07 2012-01-12 Novartis Ag CRYSTALLINE FORMS OF ALISKIREN HEMIFUMARATE N-(3-amino-2,2-dimethyl-3-oxopropyl)-2,7-di(1-methylethyl)-4-hydroxy-5-amino-8-[4-methoxy-3-(3-methoxypropoxy)phenyl]-octanamide

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Bin Peng等.Clinical Pharmacokinetics of Imatinib.《Clin Pharmacokinet》.2005,第44卷(第9期),879-894. *

Also Published As

Publication number Publication date
JP5881671B2 (ja) 2016-03-09
KR101579993B1 (ko) 2015-12-23
RU2537223C2 (ru) 2014-12-27
JP2011510086A (ja) 2011-03-31
BRPI0906504A2 (pt) 2015-07-14
EP2237783B1 (en) 2014-11-19
US9763944B2 (en) 2017-09-19
CN101951910A (zh) 2011-01-19
US20160045501A1 (en) 2016-02-18
EP2237783A1 (en) 2010-10-13
AU2009206566A1 (en) 2009-07-30
WO2009094360A1 (en) 2009-07-30
PT2237783E (pt) 2014-12-23
ES2526537T3 (es) 2015-01-13
US20100298338A1 (en) 2010-11-25
CA2712087A1 (en) 2009-07-30
US20170035757A1 (en) 2017-02-09
MX2010008103A (es) 2010-08-23
RU2010134916A (ru) 2012-02-27
JP5936821B2 (ja) 2016-06-22
JP2014094946A (ja) 2014-05-22
PL2237783T3 (pl) 2015-04-30
KR20100105778A (ko) 2010-09-29

Similar Documents

Publication Publication Date Title
US20220152026A1 (en) Pharmaceutical combination comprising tno155 and a krasg12c inhibitor
JP7671327B2 (ja) 消化管間質腫瘍の治療のための併用療法
CN112543636B (zh) 治疗与egfr突变相关的癌症的组合物和方法
US20150202203A1 (en) Method of Treating Gastrointestinal Stromal Tumors
US20150313900A1 (en) Method of treating proliferative disorders and other pathological conditions mediated by bcr-abl, c-kit, ddr1, ddr2 or pdgf-r kinase activity
Gupta et al. Ripretinib and MEK inhibitors synergize to induce apoptosis in preclinical models of GIST and systemic mastocytosis
US8673930B2 (en) Pyrimidylaminobenzamide derivatives for systemic mastocytosis
US20230056604A1 (en) Epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of cancer
JP2021522246A (ja) 癌治療のための併用
CN101951910B (zh) 优化用伊马替尼治疗酪氨酸激酶受体kit介导的增殖性疾病的制药用途
US20050075358A1 (en) Methods for treating IGF1R-inhibitor induced hyperglycemia
AU2013201993B2 (en) Method of optimizing the treatment of proliferative diseases mediated by the tyrosine kinase receptor KIT with imatinib
RU2695362C2 (ru) Новое сочетание з-[(3-{ [4-(4-морфолинилметил)-1н-пиррол-2-ил]метилен} -2-оксо-2,3-дигидро-1н-индол-5-ил)метил]-1,3-тиазолидин-2,4-диона и ингибитора тирозинкиназы egfr
WO2024088192A1 (en) An aurora a inhibitor for use in treatments of cancers
CN117940132A (zh) Erk1/2和kras g12c抑制剂组合疗法
CN120676942A (zh) 用于治疗癌症的tead抑制剂和her2抑制剂组合
JP2007507552A (ja) Ｉｇｆ１ｒ阻害剤が誘発する高血糖を治療する方法
JP2011510086A5 (https=)
CN1671389A (zh) 用于治疗间变性甲状腺癌的4－(4－甲基哌嗪－1－基甲基)－n－[4－甲基－3－基)嘧啶－2－基氨基)苯基]－苯甲酰胺

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
C56 Change in the name or address of the patentee

Owner name: NOVARTIS CO., LTD.

Free format text: FORMER NAME: NOVARTIS AG

CP01 Change in the name or title of a patent holder

Address after: Basel

Patentee after: Novartis Ag

Address before: Basel

Patentee before: Novartis AG

CF01 Termination of patent right due to non-payment of annual fee
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20130717

Termination date: 20190121